Unicycive Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
Unicycive Therapeutics, Inc. filed a current report on March 28, 2023, with the report signed on March 30, 2023. The filing concerns the Company’s compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company’s common stock trades under the symbol UNCY.
Financial and operating metrics
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Material changes versus the prior comparable period
- On August 8, 2022, Nasdaq notified the Company that its common stock had traded below the required minimum bid price of $1.00 per share for 30 consecutive business days.
- On February 1, 2023, Nasdaq notified the Company that it had not regained compliance and was not eligible for a second 180-day compliance period because it did not meet the $5 million stockholders’ equity initial listing requirement for The Nasdaq Capital Market.
- After requesting a hearing, the Company received an exception on February 28, 2023, extending the compliance period to July 24, 2023.
- On March 28, 2023, Nasdaq notified the Company that it had regained compliance with the minimum bid price requirement.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide financial guidance or operating outlook. The principal disclosed risk was the potential loss of Nasdaq listing eligibility due to the minimum bid price deficiency and the Company’s reported inability to satisfy the $5 million stockholders’ equity requirement for a second compliance period. The Company had regained compliance with the minimum bid price requirement as of March 28, 2023.
Investor verification checklist
- Verify the continued satisfaction of Nasdaq’s minimum bid price requirement after the filing date.
- Review subsequent filings for any additional Nasdaq listing deficiencies or stockholders’ equity issues.
- Assess the Company’s liquidity, capital requirements, and potential dilution using its latest periodic financial statements, as these matters are not addressed in this 8-K.
- Confirm whether any subsequent corporate actions affected the common stock price, share count, or Nasdaq listing status.